MagBio Genomics Inc. Develops Automated RNA Purification Chemistry for Mawi iSWAB-RNA v2 on Thermofisher KingFisher™ Flex
11.5.2021 16:00:00 EEST | Business Wire | Press release
Mawi DNA Technologies, a biotechnology company focusing on the development of innovative technologies for biosampling, announces that MagBio Genomics has successfully developed an automated RNA purification method for iSWAB-RNA v2 on the Thermofisher KingFisher™ Flex platform with its HighPrep™ Total RNA Isolation Kit - iSWAB™.
Mawi DNA Technologies’ iSWAB-RNA v2 allows for non-invasive self collection, concentration, and stabilization of intact buccal cells and/or any mammalian cells collected with a swab or cytobrush. It enables up to four weeks of real-time ambient stabilization of total RNA from the point of collection to processing. The high-quality RNA extracted from stabilized iSWAB-RNA v2 samples is suitable for gene expression applications such as real-time quantitative PCR, reverse transcription PCR, microarrays, northern blot analysis, nuclease protection assays, cDNA library construction and RNA-seq.
“Collaborating with MagBio Genomics to optimize their HighPrep™ Total RNA Plus Kit-iSWAB™ for iSWAB-RNA v2 was a no-brainer for us, especially because it provides a great option for our high throughput end users like pharma and CROs,” said Dr. Bassam El-Fahmawi, President and CTO, Mawi DNA Technologies. “Partnerships with leaders in nucleic acid purification chemistries with a global presence, such as MagBio Genomics, are increasing worldwide access of our sample collection technologies, which results in better understanding of health and wellness at a global rather than at a regional level.” El-Fahmawi said that due to increased sample sizes in cohort genetic population studies, there is an increasing need for automated RNA purification solutions. The MagBio HighPrep Total RNA Plus Kit-iSWAB™ simplifies this research step, which can be labor-intensive.
“MagBio has successfully developed and optimized the HighPrep™ Total RNA Isolation Kit-iSWAB™ for extraction of total RNA from iSWAB-RNA v2 samples on Thermofisher KingFisher™ Flex Purification System,” said Dr. Mothomang Mlalazi-Oyinloye, Associate Scientific Director, MagBio Genomics. “This new method is being used by a major pharmaceutical company to process iSWAB-RNA v2 samples for elucidation of molecular mechanisms of cancer development. With this automated protocol, 96 samples can be run in less than one hour.” She added that the extracted RNA is of high purity and quality and is compatible with complex and sensitive assays. RNA yields up to 1ug per sample are obtained (Qubit RNA Broad Assay).
“We are expanding our automated methods library to include the most commonly used lab automation systems,” Dr. Mlalazi-Oyinloye said. “iSWAB-RNA v2 is the non-invasive sample collection alternative to venipuncture and tissue biopsy our fellow researchers have been looking for which maintains RNA integrity especially during long transit times. MagBio Genomics is all about making the next generation sequencing workflow better. We developed an automated method for simplifying RNA purification from iSWAB-RNA v2 samples using our HighPrep™ Total RNA Plus Kit-iSWAB™,” said Dr. Hyacinth Ntchobo, CEO, MagBio Genomics. He added that when used in combination, Mawi’s iSWAB-RNA v2 collection technology and MagBio Genomics’ purification chemistry provide an efficient workflow for high throughput purification of high-quality RNA for demanding downstream applications.
About MagBio Genomics Inc.
MagBio Genomics is a global company that develops and commercializes magnetic bead-based products for nucleic acid isolation including biomarkers as tools for liquid biopsy genomic research. The current focus encompasses products that cover the complete sample preparation for NGS; from allowing safeguarding integrity of bio-samples, efficient isolation of circulating biomarkers to target enrichment from biological samples. Products are applied to human genetic research including cancer genomic studies and non-invasive prenatal testing (NIPT).“WE SIMPLY MAKE NGS BETTER.” For more information, visit http://www.magbiogenomics.com.
About Mawi DNA Technologies
Mawi DNA Technologies has developed and commercialized the iSWAB technology, an innovative system for collection of biosamples. Flagship product iSWAB-DNA has gained significant market traction due to its ability to be used for animals and all human population segments from infants to the elderly, with robust DNA yield and low bacterial DNA content. Mawi DNA has established relationships with children’s hospitals for neonatal screening and has an extensive global network of international distributors to market and sell iSWAB products. For more information, visit http://www.mawidna.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210511005456/en/
Contact information
Susan Tellem, APR, RN, BSN
310-313-3444 x1, Susan@tellemgrodypr.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alsym Energy Announces Na-Series Battery Success Developed With Physics-Informed AI Platform27.4.2026 22:25:00 EEST | Press release
Alsym Energy, a pioneer in non-flammable, high-performance sodium-ion batteries, today announced details of the proprietary physics-informed AI platform used to develop the company’s recently launched Na-Series sodium-ion batteries. By integrating fundamental physics models with AI, autonomous testing and proprietary molecular diagnostics in a closed-loop system, Alsym is accelerating the design of safer, inexpensive, commercialized batteries through all phases of the development cycle. As global demand for electricity surges, the limitations of lithium-ion batteries have become increasingly apparent, particularly around safety and supply chain constraints. Lithium-ion chemistry presents inherent challenges, including flammability and reliance on constrained global supply chains—issues that become more acute in large-scale energy storage, where higher energy densities considerably increase fire risks, and growing demand across sectors further strains the supply chain and imperils energ
Backed by Investments Exceeding $1 Billion, PCI Pharma Services Announces Major Expansion of US Sterile Fill-Finish and Drug-Device Delivery Combination Capabilities27.4.2026 17:00:00 EEST | Press release
PCI Pharma Services (“PCI”) – a world-leading integrated global contract development and manufacturing organization (CDMO) focused on innovative biologic and small molecule therapies – announced a series of major infrastructure investments that substantially deepen its sterile fill-finish and advanced drug delivery capabilities. As pharma manufacturers and their development partners increasingly prioritize US supply chain resilience, PCI’s latest investments come as part of a broader commitment exceeding $1 billion across the CDMO’s US and European operations, reinforcing its ability to provide seamless support for drug product development and manufacturing, clinical trial supply and drug-device combination assembly from clinical stages through commercial launch – all underpinned by global capacity, technical expertise, deep scientific knowledge, and an industry-leading quality and regulatory track record. This press release features multimedia. View the full release here: https://www.
Pure Lithium Appoints Renowned Battery Expert Dr. Yuan Gao to Board of Directors27.4.2026 16:53:00 EEST | Press release
Pure Lithium Corporation, a vertically integrated lithium metal battery technology company, is pleased to announce that world-renowned inventor and battery expert Dr. Yuan Gao has joined the company’s Board of Directors. Dr. Gao has been an invaluable member of Pure Lithium’s Scientific Advisory Board since October of 2023. "We are thrilled to have Dr. Gao join our board as we focus on rapidly scaling our technology in the most capital efficient manner possible,” said Pure Lithium Founder, Chairman and CEO Emilie Bodoin. “Dr. Gao is a brilliant scientist who also has deep commercial expertise, a rare combination. He is also unique in the industry because his experience spans the entire battery materials value chain, including all of Pure Lithium’s verticals. His insights over the years have been critical in advancing our technology, and his experience as a director of public companies will strengthen our board.” Dr. Gao commented: “I am thrilled to join the board of Pure Lithium Corpor
Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 202627.4.2026 16:00:00 EEST | Press release
Boomi, the data activation company, today announced Boomi World 2026, its premier annual user conference, taking place May 11 - 14, 2026 in Chicago, IL. The event will bring together customers, partners, and industry leaders from around the world to explore how data activation is transforming the enterprise and accelerating the path to AI-driven outcomes. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427600340/en/ Boomi To Unveil the Future Of Data Activation and AI-Driven Innovation at Boomi World 2026 Boomi World 2026 will spotlight data activation — bringing data to life to power AI, analytics, and intelligent automation. Attendees will gain firsthand insights into how the Boomi Enterprise Platform enables businesses to unify data, streamline operations, and innovate faster in an increasingly agentic world. “Data is only valuable when it’s activated,” said Steve Lucas, Chairman and CEO, Boomi. “At Boomi World 2026, we
Axinn Appoints Rachael Philbin as Chief Innovation Officer27.4.2026 16:00:00 EEST | Press release
Axinn, Veltrop & Harkrider LLP today announced the appointment of Rachael Philbin as Chief Innovation Officer, reinforcing the firm’s continued investment in advanced solutions and technology for legal services delivery. Philbin joins from Proskauer Rose LLP, where she served as Innovation & Transformation Officer. Based in Axinn's New York office, she will lead the firm’s AI and legal technology initiatives as well as knowledge management efforts, accelerating adoption and integration across its antitrust, intellectual property, and litigation practices. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427277725/en/ Rachael Philbin joins Axinn, Veltrop & Harkrider LLP as Chief Innovation Officer. “As Axinn continues to grow, we are making deliberate investments in the capabilities that enable our lawyers to deliver service and results at the highest level in our clients’ complex matters,” said Jeny Maier, managing partner
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
